The Rate of Decrease in the Disease Activity of Rheumatoid Arthritis during Treatment with Adalimumab Depends on the Dose of Methotrexate-Reference-Cited by-同舟云学术

The Rate of Decrease in the Disease Activity of Rheumatoid Arthritis during Treatment with Adalimumab Depends on the Dose of Methotrexate

Published:2015 Issue:9 Volume:54 Page:1035-1041
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Oh Koei¹²,Ito Satoshi²,Unno Megumi³²,Kobayashi Daisuke³²,Azuma Chinatsu⁴²,Abe Asami²,Otani Hiroshi²,Ishikawa Hajime²,Nakazono Kiyoshi²,Narita Ichiei³,Murasawa Akira²

Affiliation:

1. Department of Orthopaedic, Showa University Northern Yokohama Hospital, Japan

2. Department of Rheumatology, Niigata Rheumatic Center, Japan

3. Division of Clinical Nephrology and Rheumatology Niigata University Graduate School of Medical and Dental Sciences, Japan

4. Department of Orthopedic Surgery, University of the Ryukyus, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Reference25 articles.

1. 1. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54: 26-37, 2006.

2. 2. Smolen JS, van der Heijde DM, Keystone EC, et al. Association of joint space narrowing with impairment of physical function and work ability in patients with early rheumatoid arthritis: protection beyond disease control by adalimumab plus methotrexate. Ann Rheum Dis 72: 1156-1162, 2013.

3. 3. Takeuchi T, Tanaka Y, Kaneko Y, et al. Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study). Mod Rheumatol 22: 327-338, 2012.

4. 4. The Japan College of Rheumatology and the Institute for Data Analysis. Study of efficacy and safety of methotrexate at more than 8 mg/week: Evaluation of 3 RA patients cohorts (IORRA, REAL and NinJa) [Internet]. [cited 2014 July 15]. Available from: https://www.ryumachi-jp.com/pdf/MTXHighdose.pdf

5. 5. Koike T, Harigai M, Ishiguro N, et al. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients. Mod Rheumatol 22: 498-508, 2012.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Factors associated with subclinical inflammation of wrist joints in rheumatoid arthritis patients with low or no disease activity- a RA ultrasound registry study;BMC Musculoskeletal Disorders;2023-05-30

2. Factors associated with subclinical inflammation of wrist joints in rheumatoid arthritis patients with low or no disease activity- A RA ultrasound registry study;2022-10-10

3. Retrospective Analysis of the Impact of Adalimumab Initiation on Corticosteroid Utilization and Medical Costs Among Biologic-Naïve Patients with Rheumatoid Arthritis;Rheumatology and Therapy;2019-11-18

4. An Analysis of the Biological Disease-modifying Antirheumatic Drug-free Condition of Adalimumab-treated Rheumatoid Arthritis Patients;Internal Medicine;2019-02-15

5. Effectiveness and safety of initiating adalimumab plus ≥12 mg/week methotrexate with adjustable dosing in biologic-naïve patients with early rheumatoid arthritis: HAWK study postmarketing surveillance in Japan;Modern Rheumatology;2018-09-11